Readers like you keep news free for everyone.
More than 5,000 readers have already pitched in to keep free access to The Journal.
For the price of one cup of coffee each week you can help keep paywalls away.
Readers like you keep news free for everyone.
More than 5,000 readers have already pitched in to keep free access to The Journal.
For the price of one cup of coffee each week you can help keep paywalls away.
A BATCH OF adrenaline pens used to treat allergic reactions is being recalled.
The recall of the Emerade pens was announced today by the Health Products Regulatory Authority (HPRA).
The decision to recall a batch of the pens was made after some Emerade pens in other countries failed to produce an injection and failed to activate, with the potential for a blocked needle.
The pen is an emergency treatment for anaphylaxis.
The recall covers batches of:
Anyone who has an Emerade pen has been told by HPRA to return it to their local pharmacy and get it replaced with an alternative product.
The cause of the activation failure is unknown, as is rate of the defect in the pen.
To embed this post, copy the code below on your site